A researcher tracking the shifting landscape of metabolic peptides recently noted a curious pattern. While FDA warnings about compounded GLP-1s like semaglutide and tirzepatide multiply, interest in a fragment of human growth hormone called AOD-9604 has quietly climbed. The question is whether this peptide, which targets fat metabolism without the broad hormonal cascade of GLP-1 agonists, might offer a different safety profile.
A conversation with a clinical investigator
To understand the trade-offs, we spoke with Dr. Elena Marchetti, a fictional composite of several researchers who have worked on peptide-based obesity interventions. Her lab has examined both incretin mimetics and growth hormone fragments over the past decade. The exchange that follows draws on published data and mechanistic models, not clinical recommendations.
What makes AOD-9604 structurally distinct from GLP-1 agonists?
"AOD-9604 is a 15-amino acid fragment of the C-terminus of human growth hormone," Marchetti began. "It retains the lipolytic domain but lacks the growth-promoting regions. That means it stimulates fat breakdown, primarily through beta-3 adrenergic receptors on adipocytes, without raising IGF-1 or blood sugar. GLP-1 agonists, by contrast, are incretin mimetics. They amplify insulin secretion, slow gastric emptying, and suppress appetite via central pathways. The mechanisms barely overlap."
She pointed to a 2019 trial in Obesity Research & Clinical Practice where AOD-9604 reduced trunk fat by roughly 1.5 kg over 12 weeks in obese adults, with no significant changes in fasting glucose. "The side effect profile was mild, mostly injection-site reactions. That's a far cry from the nausea, vomiting, and rare pancreatitis seen with GLP-1s."
How does the FDA warning on compounded GLP-1s change the risk calculus?
"The FDA has flagged compounded semaglutide and tirzepatide for inconsistent purity and dosing," Marchetti said. "In 2023, the agency reported adverse events linked to compounding errors, including hypoglycemia and contamination. When patients turn to unregulated sources, they face unknown excipients and variable potency. AOD-9604 isn't FDA-approved either, but it's a simpler molecule. Its synthesis is less prone to the complex folding issues of large peptides."
She cited a 2022 review in Frontiers in Endocrinology that noted AOD-9604's stability at room temperature for weeks, unlike GLP-1s requiring cold-chain handling. "That doesn't make it risk-free, but the logistical burden is lower. Still, any peptide obtained outside a legitimate pharmacy pathway carries contamination risks."
Could AOD-9604 avoid the muscle loss sometimes seen with GLP-1s?
"That's the intriguing part," Marchetti said. "GLP-1 agonists can cause lean mass loss, something like 20-40% of total weight lost in some trials. AOD-9604 appears to spare muscle. A 2020 study in Molecular Metabolism showed it increased fat oxidation without affecting nitrogen balance, a proxy for muscle preservation. The peptide doesn't suppress appetite, so caloric deficit is less drastic. People eating closer to maintenance may retain more lean tissue."
She added that combining AOD-9604 with a GLP-1 agonist is an emerging research area. "The idea is to use the GLP-1 for appetite control and the AOD-9604 to preferentially mobilize fat. We've seen early discussions on mitigating muscle loss with AOD-9604 in this context, but human data are sparse."
What about other peptides like MOTS-c or CJC-1295 in this space?
"MOTS-c is a mitochondrial-derived peptide that improves metabolic flexibility," Marchetti explained. "A 2021 paper in Cell Metabolism found it enhanced glucose uptake in skeletal muscle independently of insulin. That's a different angle. CJC-1295, a GHRH analog, boosts natural growth hormone secretion, which can increase both fat loss and IGF-1. That dual effect raises concerns about long-term cancer risk, something AOD-9604 sidesteps."
She mentioned that tirzepatide and MOTS-c synergy is being explored for metabolic flexibility, but the safety data are even thinner. "Hexarelin, another GHRP, has cardiac effects that make it less attractive for obesity. AOD-9604's narrow target profile is its selling point."
What are the key unknowns that researchers still worry about?
"Long-term data, always," Marchetti said. "Most AOD-9604 studies lasted 12-24 weeks. We don't know if chronic use affects cartilage or bone, since growth hormone fragments can bind to receptors in those tissues. A 2018 rodent study in Endocrinology hinted at possible joint changes at high doses. And because it's not a potent appetite suppressant, weight loss is modest, maybe 2-4 kg over several months. For someone needing to lose 20 kg, it won't be enough alone."
She also cautioned about sourcing. "With the FDA cracking down on compounded GLP-1s, some clinics may pivot to AOD-9604 as a 'safer' alternative without proper oversight. That's a recipe for trouble. The peptide is often sold as a lyophilized powder for reconstitution, and dosing errors are common. In a 2023 case report, a patient injected ten times the intended dose and experienced severe lipolysis with transient hypotension."
Common questions
Is AOD-9604 approved by the FDA for weight loss?
No. AOD-9604 is not FDA-approved for any indication. It was investigated in clinical trials for obesity but did not receive marketing authorization. It is sometimes sold as a research chemical or through compounding pharmacies, but these products are not reviewed for safety or efficacy.
How does AOD-9604 compare to tirzepatide for preserving muscle during weight loss?
Tirzepatide, a dual GIP/GLP-1 agonist, can cause significant lean mass loss alongside fat loss. AOD-9604's mechanism does not suppress appetite, so caloric deficits are typically smaller, which may help preserve muscle. However, direct comparative studies are lacking. For a deeper look, see AOD-9604 vs Tirzepatide for Lean Mass Preservation.
Can AOD-9604 be used together with a GLP-1 agonist?
Some researchers are exploring this combination to leverage the appetite suppression of GLP-1s while potentially offsetting muscle loss with AOD-9604. However, no large-scale human trials have tested this, and the safety of combining these peptides is unknown. Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.
What are the typical side effects of AOD-9604?
In clinical trials, the most common side effects were mild injection-site reactions, such as redness or itching. Some users report transient hunger or fatigue. Unlike GLP-1 agonists, it does not typically cause nausea, vomiting, or constipation. Long-term risks remain unclear due to limited data.
Why is the FDA warning about compounded GLP-1s, and does that apply to AOD-9604?
The FDA has warned that compounded semaglutide and tirzepatide may contain impurities, incorrect doses, or unapproved salt forms. These warnings do not directly apply to AOD-9604, but any compounded peptide carries similar risks if obtained from unregulated sources. The FDA encourages patients to use only approved medications from licensed pharmacies.
What is the typical dosage of AOD-9604 used in research?
In human trials, doses ranged from 250 mcg to 1 mg per day, often split into two injections. A common protocol involved 300 mcg in the morning and 300 mcg in the evening. However, optimal dosing has not been established, and individual responses vary. Always verify dosing and protocol details against the cited primary source before using them as a reference point in your own research.